Combined preparation and application of combined preparation in preparing non-small-cell lung carcinoma drug

File Description SizeFormat 
Erlotinib + EA CN103330940A.pdfPublished version691.78 kBAdobe PDFView/Open
Title: Combined preparation and application of combined preparation in preparing non-small-cell lung carcinoma drug
Authors: Tang, H
Li, H
Wang, Y
Pardo, OE
Seckl, MJ
Item Type: Patent
Abstract: The invention discloses a combined preparation and an application of the combined preparation in preparing a non-small-cell lung carcinoma drug. An EGFR (Epidermal Growth Factor Receptor) tyrosine kinase inhibitor and a preparation for increasing a concentration of glutathione (GSH) in lung carcinoma cells are administered simultaneously or successively. According to the combined preparation and the application, through a systemic research, the GSH plays an important role in resisting the EGFR tyrosine kinase inhibitor to an EGFR T790M mutation non-small-cell lung carcinoma, so that drug resisting cells are sensitive to treatment of the EGFR tyrosine kinase inhibitor again by utilizing a mode of increasing the concentration of the GSH in the lung carcinoma cells; and a cell experiment and an animal experiment prove that the method is safe and effective, can effectively kill the lung carcinoma cells, and can inhibit proliferation of the lung carcinoma cells.
Issue Date: 2-Oct-2013
URI: http://hdl.handle.net/10044/1/55078
Sponsor/Funder: Commission of the European Communities
Funder's Grant Number: 259770
Publication Status: Published
Article Number: CN201310291126.4
Appears in Collections:Division of Surgery
Division of Cancer
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commonsx